<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MIN</journal-id>
<journal-id journal-id-type="hwp">spmin</journal-id>
<journal-title>Menopause International</journal-title>
<issn pub-type="ppub">1754-0453</issn>
<issn pub-type="epub">1754-0461</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1754045313481536</article-id>
<article-id pub-id-type="publisher-id">10.1177_1754045313481536</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The management of lower urogenital changes in the menopause</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Singh</surname><given-names>Savita</given-names></name>
<xref ref-type="aff" rid="aff1-1754045313481536">1</xref>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Herwijnen</surname><given-names>Ineke van</given-names></name>
<xref ref-type="aff" rid="aff2-1754045313481536">2</xref>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Phillips</surname><given-names>Christian</given-names></name>
<xref ref-type="aff" rid="aff1-1754045313481536">1</xref>
<xref ref-type="corresp" rid="corresp1-1754045313481536"/>
</contrib>
</contrib-group>
<aff id="aff1-1754045313481536"><label>1</label>Hampshire Hospitals NHS Foundation Trust, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, Hants, UK</aff>
<aff id="aff2-1754045313481536"><label>2</label>Obstetrics and Gynaecology, Princess Anne Hospital, Southampton, Hampshire, UK</aff>
<author-notes>
<corresp id="corresp1-1754045313481536">Christian Phillips, Hampshire Hospitals NHS Foundation Trust, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke, Hants RG24 9NA, UK. Email: <email>philipschaps@aol.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>2</issue>
<fpage>77</fpage>
<lpage>81</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">British Menopause Society</copyright-holder>
</permissions>
<abstract>
<p>Currently, 25% of women seek the advice of a medical professional for symptoms related to the menopause. However, with an increasingly ageing and medically aware population, it is likely this proportion will grow. The main symptoms related to the menopause are systemic vasomotor and localized urogenital symptoms. Numerous forms of estrogen have been used to alleviate these symptoms. Further problems that increase during the menopause include incontinence, pelvic organ prolapse and recurrent urinary tract infections. This article reviews the process by which estrogen affects the tissues of the urogenital tract, what symptoms occur during this period and what modalities of treatments are available.</p>
</abstract>
<kwd-group>
<kwd>Urogenital atrophy</kwd>
<kwd>incontinence</kwd>
<kwd>estrogen</kwd>
<kwd>prolapse</kwd>
<kwd>menopause</kwd>
<kwd>hormone therapy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1754045313481536" sec-type="intro"><title>Introduction</title>
<p>The female genital and lower urinary tract have the same embryological origin; both arising from the urogenital sinus and consequently are both sensitive to the effects of female sex steroid hormones.<sup><xref ref-type="bibr" rid="bibr1-1754045313481536">1</xref></sup> Estrogen and progesterone receptors have been isolated in the urogenital tract, which encompasses the vagina, bladder, urethra and pelvic floor musculature.<sup><xref ref-type="bibr" rid="bibr2-1754045313481536">2</xref></sup> The menopause is defined as the permanent cessation of menses resulting from the loss of ovarian follicular activity.<sup><xref ref-type="bibr" rid="bibr3-1754045313481536">3</xref></sup> The characteristic features of reduced estrogen are systemic including vasomotor symptoms and localized atrophy of the urogenital tract<sup><xref ref-type="bibr" rid="bibr3-1754045313481536">3</xref></sup> The use of systemic hormone therapy in optimizing changes associated with the menopause was once accepted as the ideal approach; however, some studies have challenged this view which has led to the decrease in the use of high-dose systemic treatment and has increased the search for low-dose topical therapies.<sup><xref ref-type="bibr" rid="bibr4-1754045313481536">4</xref></sup></p>
</sec>
<sec id="sec2-1754045313481536"><title>Estrogen receptors in the lower urogenital system</title>
<p>The effects of the steroid hormones 17β-estradiol (E2) are mediated by ligand-activated transcription factors known as estrogen receptors<sup><xref ref-type="bibr" rid="bibr5-1754045313481536">5</xref></sup> located in the nucleus of the cell. Two estrogen receptors have been identified; α discovered in 1986<sup><xref ref-type="bibr" rid="bibr6-1754045313481536">6</xref></sup> and β discovered in 1997.<sup><xref ref-type="bibr" rid="bibr7-1754045313481536">7</xref>,<xref ref-type="bibr" rid="bibr8-1754045313481536">8</xref></sup> The estrogen receptor is found in the trigone, of the bladder, the proximal and distal urethra but not in the dome of the bladder. It is also found in vaginal squamous epithelium.<sup><xref ref-type="bibr" rid="bibr9-1754045313481536">9</xref></sup> Chen et al.<sup><xref ref-type="bibr" rid="bibr8-1754045313481536">8</xref></sup> found that estrogen receptors were also present in the pubococcygeus muscle and the urethral sphincter. Press et al.<sup><xref ref-type="bibr" rid="bibr10-1754045313481536">10</xref></sup> showed that in premenopausal women, the expression of estrogen receptors in genital tract changed over the course of the menstrual cycle. Two out of three women report vaginal symptoms associated with urogenital atrophy by the age of 70, but only 20% seek medical help.<sup><xref ref-type="bibr" rid="bibr11-1754045313481536">11</xref></sup> The delay in symptom development for more than 10 years after their last menstrual period<sup><xref ref-type="bibr" rid="bibr12-1754045313481536">12</xref></sup> may be due to a change in expression of estrogen receptors.<sup><xref ref-type="bibr" rid="bibr10-1754045313481536">10</xref></sup></p>
<p>The maturation of vaginal tissue can be measured by vaginal cytology and is scored using the vaginal maturation index.<sup><xref ref-type="bibr" rid="bibr13-1754045313481536">13</xref></sup> This assesses the percentage of parabasal/intermediate/superficial cells that are shed. A ‘shift to the left’ with more parabasal cells indicates vaginal atrophy as there are more immature cells. A ‘shift to the right’ indicates more mature epithelium and consequently less atrophy. Estrogen deficiency causes a decrease in superficial cells and a relative increase in the proportion of intermediate and parabasal cells. A reduction in superficial cells results in a decrease in glycogen levels within the tissue, which inhibits lactic acid production by the vaginal flora. These changes increase the vaginal pH and consequently cause a change in the microflora and may render the vagina more susceptible to the cultivation of fungal and bacterial infections.<sup><xref ref-type="bibr" rid="bibr14-1754045313481536">14</xref></sup></p>
</sec>
<sec id="sec3-1754045313481536"><title>Management of urogenital atrophy</title>
<p>Vaginal estrogens are the preferred therapy for isolated lower urogenital symptoms.<sup><xref ref-type="bibr" rid="bibr15-1754045313481536">15</xref></sup> In a meta-analysis of 10 trials, local estrogen therapy was as effective as systemic therapy when assessing symptomatic improvement in vulvo-vaginal atrophy.<sup><xref ref-type="bibr" rid="bibr16-1754045313481536">16</xref></sup> Non-hormonal management of urogenital atrophy is also suitable for those who do not want to consider hormonal intervention. These include lifestyle management, vaginal moisturizer and lubricants.<sup><xref ref-type="bibr" rid="bibr17-1754045313481536">17</xref></sup> Symptoms of urogenital atrophy do not occur until the level of endogenous estrogen is much lower than that required to cause endometrial proliferation.<sup><xref ref-type="bibr" rid="bibr18-1754045313481536">18</xref></sup> Consequently, it is possible to use low-dose estrogen replacement therapy in order to reduce urogenital atrophy symptoms whilst avoiding the risk of endometrial proliferation, thus negating the need to protect the endometrium with progesterone.<sup><xref ref-type="bibr" rid="bibr19-1754045313481536">19</xref></sup></p>
<p>A Cochrane meta-analysis (16 trials: 2129 women in total) showed that topical estrogens were better than both placebo and non-hormonal gel in the management of urogenital atrophy.<sup><xref ref-type="bibr" rid="bibr20-1754045313481536">20</xref></sup> There are a variety of different vectors by which estrogen can be applied locally. These include creams, rings and vaginal tablets. The review concluded the efficacy for all local estrogen therapies were found to be the same; however, some estrogen creams were associated with an increased risk of systemic absorption.<sup><xref ref-type="bibr" rid="bibr20-1754045313481536">20</xref></sup> Consequently, conjugated equine estrogen cream has been withdrawn.</p>
<sec id="sec4-1754045313481536"><title>Estradiol ring</title>
<p>The estradiol ring continually releases approximately 7.5 µg of estradiol over a period of 24 h for up to 90 days. The ring has proven superior to both placebo or no treatment and to be just as effective as vaginal tablets and creams in the relief of symptoms as well as reducing vaginal pH levels and maturing the vaginal mucosa.<sup><xref ref-type="bibr" rid="bibr21-1754045313481536">21</xref></sup> The vaginal ring is self-inserted and can be changed every three months. In patients with limited manual dexterity or vaginal capacity, the ring can be inserted by a doctor. An open-label trial of 129 women demonstrated that treatment with the ring was related to a rise in bone density suggesting a degree of systemic absorbtion.<sup><xref ref-type="bibr" rid="bibr22-1754045313481536">22</xref></sup></p>
</sec>
<sec id="sec5-1754045313481536"><title>Vaginal tablets (17 β-estradiol)</title>
<p>Estradiol hemihydrate 25 µg (Vagifem 25 µg®) was discontinued as of December 2012 responding to recent recommendations from the International Menopause society that state best practice is to use the lowest effective dose of HRT where possible.<sup><xref ref-type="bibr" rid="bibr23-1754045313481536">23</xref></sup> Ultra-low-dose vaginal estradiol (Estradiol hemihydrate 10 µg) allows similar symptomatic improvement with similar improvements in vaginal cytology, urethral cytology and vaginal pH when compared with the 25 µg preparation, with no effect on endometrial proliferation and serum estrogen levels remaining in the normal postmenopausal range.<sup><xref ref-type="bibr" rid="bibr24-1754045313481536">24</xref></sup> Another randomized controlled trial studying the effects of estradiol hemihydrate 25 µg and estradiol hemihydrate 10 µg in 58 women showed that only 74% of women on estradiol hemihydrate 25 µg had estradiol in the normal range for a postmenopausal woman, comparing with 96% in the estradiol hemihydrate 10 µg group.<sup><xref ref-type="bibr" rid="bibr25-1754045313481536">25</xref></sup> Endometrial safety associated with estradiol hemihydrate 10 µg was evaluated by endometrial biopsy over two 52-week clinical trials; these showed that there was no significant increase in the development of endometrial hyperplasia or cancer above the background rate of 0–1%.<sup><xref ref-type="bibr" rid="bibr26-1754045313481536">26</xref></sup> Further studies have found that there was no evidence of endometrial thickening on ultrasound after 12 months usage of estradiol hemihydrate 10 µg.<sup><xref ref-type="bibr" rid="bibr26-1754045313481536">26</xref></sup> A multicenter randomized double-blind parallel group study involving 230 women had treatment of estradiol hemihydrate 25 µg, estradiol hemihydrate 10 µg or placebo for 12 weeks. Results showed that estradiol hemihydrate 10 µg was as effective in treating symptoms as the estradiol hemihydrate 25 µg dose.<sup><xref ref-type="bibr" rid="bibr27-1754045313481536">27</xref></sup></p>
</sec>
</sec>
<sec id="sec6-1754045313481536"><title>Stress incontinence</title>
<p>The prevalence of both stress urinary incontinence (UI) and urge incontinence increases steadily after the menopause, although the prevalence of stress incontinence reduces after the age of 65 but still remains far higher than premenopausal values.<sup><xref ref-type="bibr" rid="bibr28-1754045313481536">28</xref></sup> Stress incontinence is defined by NICE as the involuntary urine leakage on effort or exertion or on sneezing or coughing.<sup><xref ref-type="bibr" rid="bibr29-1754045313481536">29</xref></sup> It is believed that stress incontinence is due to poor urethral support. The supporting structures to the urethra and bladder neck comprised the muscles of the pelvic floor along with their intact nerve supply and the sub-urethral endopelvic fascia, which is mainly composed of collagen. Studies looking at collagen turnover have demonstrated a difference in collagen remodeling in premenopausal women with stress incontinence compared with continent controls. Stress incontinence is associated with a change in collagen content including a reduction in total collagen concentration,<sup><xref ref-type="bibr" rid="bibr30-1754045313481536">30</xref></sup> a decrease in collagen cross linking<sup><xref ref-type="bibr" rid="bibr31-1754045313481536">31</xref></sup> and an increase in the level of collagen turnover markers.<sup><xref ref-type="bibr" rid="bibr32-1754045313481536">32</xref></sup> One hypothesis to support the use of systemic or local estrogen therapy in the management of lower urinary tract dysfunction in the postmenopausal population suggests that estrogens stimulate a strengthening in connective tissues. Six-month estrogen therapy does stimulate greater collagen degradation and the laying down of new collagen (which may be stronger) compared with placebo in postmenopausal women with stress incontinence.<sup><xref ref-type="bibr" rid="bibr33-1754045313481536">33</xref></sup> Urodynamic evaluation has also shown that oral estrogen increases maximum urethral pressure and leads to symptomatic improvement in 65–70% of women.<sup><xref ref-type="bibr" rid="bibr34-1754045313481536">34</xref></sup> However, there is no evidence to suggest whether this is attributed to changes in the muscle, connective tissue or properties in the urothelium. Unfortunately, in clinical practice, a placebo controlled study failed to show any difference in either subjective or objective symptoms of stress incontinence in postmenopausal women after six months estrogen therapy compared with controls.<sup><xref ref-type="bibr" rid="bibr35-1754045313481536">35</xref></sup></p>
</sec>
<sec id="sec7-1754045313481536"><title>Detrusor overactivity</title>
<p>Overactive bladder syndrome (OAB) is defined as urgency that occurs with or without urge UI and usually with frequency and nocturia.<sup><xref ref-type="bibr" rid="bibr29-1754045313481536">29</xref></sup> On urodynamics, it can be identified by a rise in detrusor pressure during the filling phase. Although estrogen receptors are absent in the transitional epithelium of the dome of the bladder, they are present in the trigone.<sup><xref ref-type="bibr" rid="bibr9-1754045313481536">9</xref></sup> Estrogen is known to have an effect on detrusor function by modifying the muscarinic receptors<sup><xref ref-type="bibr" rid="bibr36-1754045313481536">36</xref></sup> and inhibiting the movement of Ca<sup>2+</sup> into muscle cells.<sup><xref ref-type="bibr" rid="bibr37-1754045313481536">37</xref></sup> By this mechanism, estrogen may reduce the amplitude and frequency of spontaneous detrusor contractions and can improve the sensory threshold in some women.</p>
<p>There has been conflicting evidence for the use of oral estrogen therapy to improve symptoms of OAB, as much of the data comes from observational studies.<sup><xref ref-type="bibr" rid="bibr38-1754045313481536">38</xref></sup> Cardozo et al.<sup><xref ref-type="bibr" rid="bibr39-1754045313481536">39</xref></sup> found both subjective and urodynamic improvement in OAB symptoms in women taking estrogen compared with placebo; however, this was not statistically significant. Benness et al.<sup><xref ref-type="bibr" rid="bibr40-1754045313481536">40</xref></sup> found a statistically significant improvement in urgency in women taking vaginal estrogen compared with placebo. More recently, a review of 10 RCTs showed that estrogen was superior to placebo when considering symptoms of urge incontinence, frequency and nocturia, although vaginal estrogen administration was found to be superior for symptoms of urgency. In those patients taking estrogens, there also was a significant increase in first sensation and bladder capacity compared with a placebo.<sup><xref ref-type="bibr" rid="bibr41-1754045313481536">41</xref></sup></p>
</sec>
<sec id="sec8-1754045313481536"><title>Recurrent urinary tract infection</title>
<p>The NICE definition of recurrent urinary tract infections (RUTIs) is as follows:
<list id="list1-1754045313481536" list-type="bullet">
<list-item><p>Two or more episodes of UTI with acute pyelonephritis/upper urinary tract infection,</p></list-item>
<list-item><p>One episode of UTI with acute pyelonephritis/upper urinary tract infection plus one or more episode of UTI with cystitis/lower urinary tract infection or</p></list-item>
<list-item><p>Three or more episodes of UTI with cystitis/lower urinary tract infection.</p></list-item>
</list></p>
<p>The main factors associated with RUTI in postmenopausal women are UI, prolapse including cystocoele and a large post-void residual, all of which have been associated with estrogen deficiency.<sup><xref ref-type="bibr" rid="bibr42-1754045313481536">42</xref></sup> It is thought that estrogen therapy can reduce RUTI by improving the maturation of the vaginal and urethral epithelium<sup><xref ref-type="bibr" rid="bibr40-1754045313481536">40</xref></sup> and reducing the vaginal pH to reverse the microbiological overgrowth that can occur during the menopause.<sup><xref ref-type="bibr" rid="bibr43-1754045313481536">43</xref></sup> A review of the role of estrogens in the prevention of RUTI found that oral estrogen was as effective as oral antibiotic prophylaxis but had systemic side effects that were troublesome to the patient and so concluded that local estrogen may play a role in RUTI where antibiotic therapy cannot be tolerated by the patient.<sup><xref ref-type="bibr" rid="bibr44-1754045313481536">44</xref></sup></p>
</sec>
<sec id="sec9-1754045313481536"><title>Prolapse</title>
<p>The International Continence Society defines pelvic organ prolapse (POP) as the downward descent of pelvic organs, which results in a protrusion of the vagina and/or cervix.<sup><xref ref-type="bibr" rid="bibr45-1754045313481536">45</xref></sup> The pelvic organs are supported by levator ani (pubococcygeus, iliococcygeus and ischiococcygeus) and suspensory (uterosacral and cardinal) ligaments, which are condensations of the endopelvic fascia. Both estrogen receptors (<bold>α</bold> and <bold>β</bold>) have been identified in the pubococcygeous muscle as well as vaginal walls and uterosacral ligaments of premenouasal women.<sup><xref ref-type="bibr" rid="bibr46-1754045313481536">46</xref></sup> Limited evidence has shown a reduction in the number of estrogen receptors in the pelvic organs after the menopause.<sup><xref ref-type="bibr" rid="bibr47-1754045313481536">47</xref></sup> On the strength of this, it has been suggested that an estrogen-deficient state may weaken the supporting ligaments of the pelvic floor, leading to prolapse.<sup><xref ref-type="bibr" rid="bibr47-1754045313481536">47</xref></sup></p>
<p>Selective estrogen receptor modulators (SERMs) mediate their effect through the estrogen receptor. Both raloxifene and tamoxifen have been shown to be associated with a trend toward increased POP (demonstrated by the POP-Q scale).<sup><xref ref-type="bibr" rid="bibr48-1754045313481536">48</xref></sup> Currently, there is no evidence to prove that the administration of systemic or topical estrogen therapy improves POP unless symptoms are due to atrophy rather than prolapse.<sup><xref ref-type="bibr" rid="bibr13-1754045313481536">13</xref></sup> However, topical estrogen cream can be of benefit in patients with ulceration secondary to procidentia or pessaries, and as a pre-treatment prior to prolapse surgery to improve vaginal tissues.</p>
</sec>
<sec id="sec10-1754045313481536" sec-type="conclusions"><title>Conclusion</title>
<p>In conclusion, urogenital symptoms associated with estrogen deficiency remain a troubling aspect of the menopause. Topical estrogens have been shown to be effective in managing symptoms of urogenital atrophy. There are a variety of different vectors used to administer estrogen. The International Menopause Society recommends using the lowest dose wherever possible. There is no evidence to suggest estrogens are useful in the treatment of stress incontinence. However, topical estrogens do improve symptoms of urgency in women with detrusor overactivity. Topical estrogen therapy is as efficacious as prophylactic low-dose antibiotics in preventing recurrent urinary tract infections but has greater systemic side effects. For those patients who find oral antibiotics intolerable, it remains a good alternative. Estrogens are not useful in treating POP. Anecdotal evidence suggests topical therapy is useful as an adjunct to pessary usage or prior to surgery.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-1754045313481536"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iosif</surname><given-names>CS</given-names></name><name><surname>Batra</surname><given-names>S</given-names></name><name><surname>Ek</surname><given-names>A</given-names></name></person-group>. <article-title>Estrogen receptors in the human female lower urinary tract</article-title>. <source>Am J Obstet Gynaecol</source> <year>1981</year>; <volume>141</volume>: <fpage>817</fpage>–<lpage>820</lpage>.</citation></ref>
<ref id="bibr2-1754045313481536"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Batra</surname><given-names>S</given-names></name><name><surname>Iosif</surname><given-names>S</given-names></name></person-group>. <article-title>Progesterone receptors in the female lower urinary</article-title>. <source>J Urol</source> <year>1987</year>; <volume>138</volume>: <fpage>1301</fpage>–<lpage>1307</lpage>.</citation></ref>
<ref id="bibr3-1754045313481536"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teede</surname><given-names>HJ</given-names></name><name><surname>Vincent</surname><given-names>A</given-names></name></person-group>. <article-title>Hormone therapy – where are we now?</article-title> <source>Aust Fam Phys</source> <year>2011</year>; <volume>40</volume>: <fpage>2011</fpage>–<lpage>2011</lpage>.</citation></ref>
<ref id="bibr4-1754045313481536"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chollet</surname><given-names>JA</given-names></name></person-group>. <article-title>Efficacy and safety of ultra-low-dose Vagifem (10 mcg)</article-title>. <source>Patient Prefer Adherence</source> <year>2011</year>; <volume>5</volume>: <fpage>571</fpage>–<lpage>574</lpage>.</citation></ref>
<ref id="bibr5-1754045313481536"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>M</given-names></name><name><surname>Nilsson</surname><given-names>S</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name></person-group>. <article-title>The oestrogen receptor family</article-title>. <source>Curr Opin Obstet Gynecol</source> <year>1999</year>; <volume>11</volume>: <fpage>249</fpage>–<lpage>254</lpage>.</citation></ref>
<ref id="bibr6-1754045313481536"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>S</given-names></name><name><surname>Walter</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Human oestrogen receptor cDNA: sequence, expression and homology to v-erbA</article-title>. <source>Nature</source> <year>1986</year>; <volume>320</volume>: <fpage>134</fpage>–<lpage>139</lpage>.</citation></ref>
<ref id="bibr7-1754045313481536"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>G</given-names></name><name><surname>Enmark</surname><given-names>E</given-names></name><name><surname>Pelto-Huikko</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cloning of a novel oestrogen receptor expressed in rat prostrate and ovary</article-title>. <source>Proc Natl Acad Sci USA</source> <year>1996</year>; <volume>93</volume>: <fpage>5925</fpage>–<lpage>5930</lpage>.</citation></ref>
<ref id="bibr8-1754045313481536"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>GD</given-names></name><name><surname>Oliver</surname><given-names>RH</given-names></name><name><surname>Leung</surname><given-names>BS</given-names></name><etal/></person-group>. <article-title>Oestrogen receptor α and β expression in the vaginal walls and uterosacral ligaments of premenopausal and postmenopausal women</article-title>. <source>Fertil Steril</source> <year>1999</year>; <volume>71</volume>: <fpage>1099</fpage>–<lpage>1102</lpage>.</citation></ref>
<ref id="bibr9-1754045313481536"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blakeman</surname><given-names>PJ</given-names></name><name><surname>Hilton</surname><given-names>P</given-names></name><name><surname>Bulmer</surname><given-names>JN</given-names></name></person-group>. <article-title>Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status</article-title>. <source>BJU Int</source> <year>2000</year>; <volume>86</volume>: <fpage>32</fpage>–<lpage>38</lpage>.</citation></ref>
<ref id="bibr10-1754045313481536"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Press</surname><given-names>MF</given-names></name><name><surname>Nousek-Goebl</surname><given-names>NA</given-names></name><name><surname>Bur</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Estrogen receptor localization in the female genital tract</article-title>. <source>Am J Pathol</source> <year>1986</year>; <volume>123</volume>: <fpage>280</fpage>–<lpage>292</lpage>.</citation></ref>
<ref id="bibr11-1754045313481536"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cumming</surname><given-names>GP</given-names></name><name><surname>Herald</surname><given-names>J</given-names></name><name><surname>Moncur</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Women’s attitudes to hormone replacement therapy, alternative treatments and sexual health</article-title>. <source>Menopause Int</source> <year>2007</year>; <volume>13</volume>: <fpage>79</fpage>–<lpage>83</lpage>.</citation></ref>
<ref id="bibr12-1754045313481536"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iosif</surname><given-names>CS</given-names></name></person-group>. <article-title>Effects of protracted administration of oestriol on the lower genitourinary tract in postmenopausal women</article-title>. <source>Acta Obstet Gynaecol Scand</source> <year>1992</year>; <volume>251</volume>: <fpage>115</fpage>–<lpage>120</lpage>.</citation></ref>
<ref id="bibr13-1754045313481536"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>K</given-names></name><name><surname>Risberg</surname><given-names>B</given-names></name><name><surname>Heimer</surname><given-names>G</given-names></name></person-group>. <article-title>The vaginal epithelium in the postmenopause – cytology, histology and pH as methods of assessment</article-title>. <source>Maturitas</source> <year>1995</year>; <volume>21</volume>: <fpage>51</fpage>–<lpage>56</lpage>.</citation></ref>
<ref id="bibr14-1754045313481536"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bachmann</surname><given-names>GA</given-names></name><name><surname>Nevadunsky</surname><given-names>NS</given-names></name></person-group>. <article-title>Diagnosis and treatment of atrophic vaginitis</article-title>. <source>Am Fam Physician</source> <year>2000</year>; <volume>61</volume>: <fpage>3090</fpage>–<lpage>3096</lpage>.</citation></ref>
<ref id="bibr15-1754045313481536"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hickey</surname><given-names>M</given-names></name><name><surname>Saunders</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer</article-title>. <source>Ann Oncol</source> <year>2008</year>; <volume>19</volume>: <fpage>1669</fpage>–<lpage>1680</lpage>.</citation></ref>
<ref id="bibr16-1754045313481536"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cardozo</surname><given-names>LD</given-names></name><name><surname>Bachmann</surname><given-names>G</given-names></name><name><surname>McClish</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Meta-analysis of oestrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee</article-title>. <source>Obstet Gynaecol</source> <year>1998</year>; <volume>92</volume>: <fpage>722</fpage>–<lpage>727</lpage>.</citation></ref>
<ref id="bibr17-1754045313481536"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>SL</given-names></name><name><surname>Farrell</surname><given-names>SA</given-names></name></person-group>. <article-title>The detection and management of vaginal atrophy. [SOGC Clinical Practice Guideline No. 145]</article-title>. <source>J Obstet Gynaecol Can</source> <year>2004</year>; <volume>26</volume>: <fpage>503</fpage>–<lpage>508</lpage>.</citation></ref>
<ref id="bibr18-1754045313481536"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samicoe</surname><given-names>G</given-names></name></person-group>. <article-title>Urogenital ageing – a hidden problem</article-title>. <source>Am J Obstet Gynaecol</source> <year>1998</year>; <volume>178</volume>: <fpage>S245</fpage>–<lpage>S249</lpage>.</citation></ref>
<ref id="bibr19-1754045313481536"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mettler</surname><given-names>L</given-names></name><name><surname>Olsen</surname><given-names>PG</given-names></name></person-group>. <article-title>Long term treatment of atrophic vaginitis with low dose oestradiol vaginal tablets</article-title>. <source>Maturitas</source> <year>1991</year>; <volume>14</volume>: <fpage>23</fpage>–<lpage>31</lpage>.</citation></ref>
<ref id="bibr20-1754045313481536"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suckling</surname><given-names>J</given-names></name><name><surname>Lethaby</surname><given-names>A</given-names></name><name><surname>Kennedy</surname><given-names>R</given-names></name></person-group>. <article-title>Local oestrogen for vaginal atrophy in postmenopausal women</article-title>. <source>Cochrane Database Syst Rev</source> <year>2003</year>; <volume>4</volume>: <fpage>CD001500</fpage>–<lpage>CD001500</lpage>.</citation></ref>
<ref id="bibr21-1754045313481536"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crandall</surname><given-names>C</given-names></name></person-group>. <article-title>Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy</article-title>. <source>J Womens Health (Larchmt)</source> <year>2002</year>; <volume>11</volume>: <fpage>857</fpage>–<lpage>877</lpage>.</citation></ref>
<ref id="bibr22-1754045313481536"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naessen</surname><given-names>T</given-names></name><name><surname>Berglund</surname><given-names>L</given-names></name><name><surname>Ulmsten</surname><given-names>U</given-names></name></person-group>. <article-title>Bone loss in elderly women prevented by ultralow doses of parenteral 17 beta-estradiol</article-title>. <source>Am J Obstet Gynecol</source> <year>1997</year>; <volume>177</volume>: <fpage>115</fpage>–<lpage>119</lpage>.</citation></ref>
<ref id="bibr23-1754045313481536"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sturdee</surname><given-names>DW</given-names></name><name><surname>Panay</surname><given-names>N</given-names></name></person-group>. <collab>on behalf of the International Menopause Society Writing Group</collab>. <article-title>Recommendations for the management of postmenopausal vaginal atrophy</article-title>. <source>Climacteric</source> <year>2010</year>; <volume>13</volume>: <fpage>509</fpage>–<lpage>522</lpage>.</citation></ref>
<ref id="bibr24-1754045313481536"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santen</surname><given-names>RJ</given-names></name><name><surname>Pinkerton</surname><given-names>JV</given-names></name><name><surname>Conaway</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Treatment of urogenital atrophy with low dose oestradiol: preliminary results</article-title>. <source>Menopause</source> <year>2002</year>; <volume>9</volume>: <fpage>179</fpage>–<lpage>187</lpage>.</citation></ref>
<ref id="bibr25-1754045313481536"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Notelovitz</surname><given-names>M</given-names></name><name><surname>Funk</surname><given-names>S</given-names></name><name><surname>Nanavati</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Oestradiol absorption from vaginal tablets in postmenopausal women</article-title>. <source>Obstet Gynaecol</source> <year>2002</year>; <volume>99</volume>: <fpage>556</fpage>–<lpage>562</lpage>.</citation></ref>
<ref id="bibr26-1754045313481536"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ulrich</surname><given-names>LS</given-names></name><name><surname>Naessen</surname><given-names>T</given-names></name><name><surname>Elia</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy</article-title>. <source>Climacteric</source> <year>2010</year>; <volume>13</volume>: <fpage>228</fpage>–<lpage>237</lpage>.</citation></ref>
<ref id="bibr27-1754045313481536"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bachmann</surname><given-names>G</given-names></name><name><surname>Lobo</surname><given-names>RA</given-names></name><name><surname>Gut</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial</article-title>. <source>Obstet Gynecol</source> <year>2008</year>; <volume>111</volume>: <fpage>67</fpage>–<lpage>76</lpage>.</citation></ref>
<ref id="bibr28-1754045313481536"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>A</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Prevalence of hand washing urinary incontinence in females in comparison with stress and urge incontinence</article-title>. <source>Neurourol Urodyn</source> <year>1990</year>; <volume>9</volume>: <fpage>330</fpage>–<lpage>331</lpage>.</citation></ref>
<ref id="bibr29-1754045313481536"><label>29</label><citation citation-type="other"><comment>NICE guideline: CG40 Urinary incontinence, 23 October 2006</comment>.</citation></ref>
<ref id="bibr30-1754045313481536"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keane</surname><given-names>DP</given-names></name><name><surname>Sims</surname><given-names>TJ</given-names></name><name><surname>Abrams</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Analysis of collagen status in premenopausal nulliparous women with genuine stress incontinence</article-title>. <source>Br J Obstet Gynaecol</source> <year>1997</year>; <volume>104</volume>: <fpage>994</fpage>–<lpage>998</lpage>.</citation></ref>
<ref id="bibr31-1754045313481536"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falconer</surname><given-names>C</given-names></name><name><surname>Blomgren</surname><given-names>B</given-names></name><name><surname>Johansson</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Different organization of collagen fibrils in stress-incontinent women of fertile age</article-title>. <source>Acta Obstet Gynecol Scand</source> <year>1998</year>; <volume>77</volume>: <fpage>87</fpage>–<lpage>94</lpage>.</citation></ref>
<ref id="bibr32-1754045313481536"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwall</surname><given-names>L</given-names></name><name><surname>Carlström</surname><given-names>K</given-names></name><name><surname>Jonasson</surname><given-names>AF</given-names></name></person-group>. <article-title>Endocrine status and markers of collagen synthesis and degradation in serum and urogenital tissue from women with and without stress urinary incontinence</article-title>. <source>Neurourol Urodyn</source> <year>2007</year>; <volume>26</volume>: <fpage>410</fpage>–<lpage>415</lpage>.</citation></ref>
<ref id="bibr33-1754045313481536"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>M</given-names></name><name><surname>Abrams</surname><given-names>P</given-names></name></person-group>. <article-title>The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence</article-title>. <source>Br J Obstet Gynaecol</source> <year>2002</year>; <volume>109</volume>: <fpage>339</fpage>–<lpage>344</lpage>.</citation></ref>
<ref id="bibr34-1754045313481536"><label>34</label><citation citation-type="other"><comment>Caine M and Raz S. The role of female hormones in stress incontinence. In: <italic>Proceedings of the 16th Congress of the International Society of Urology</italic>, Amsterdam, The Netherlands</comment>.</citation></ref>
<ref id="bibr35-1754045313481536"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>S</given-names></name><name><surname>Shepherd</surname><given-names>A</given-names></name><name><surname>Brookes</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind, placebo controlled trial</article-title>. <source>Br J Obstet Gynaecol</source> <year>1999</year>; <volume>106</volume>: <fpage>711</fpage>–<lpage>718</lpage>.</citation></ref>
<ref id="bibr36-1754045313481536"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>E</given-names></name></person-group>. <article-title>Effect of estrogens on the weight and muscarinic cholinergic receptor density of the rabbit bladder and urethra</article-title>. <source>J Urol</source> <year>1986</year>; <volume>135</volume>: <fpage>1084</fpage>–<lpage>1087</lpage>.</citation></ref>
<ref id="bibr37-1754045313481536"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>RA</given-names></name><name><surname>Castleden</surname><given-names>CM</given-names></name><name><surname>Miodrag</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The direct effects of diethylstilboestrol and nifedipine on the contractile responses of isolated human and rat detrusor muscles</article-title>. <source>Eur J Clin Pharmacol</source> <year>1992</year>; <volume>43</volume>: <fpage>149</fpage>–<lpage>155</lpage>.</citation></ref>
<ref id="bibr38-1754045313481536"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koski</surname><given-names>ME</given-names></name><name><surname>Chermansky</surname><given-names>CJ</given-names></name></person-group>. <article-title>Does estrogen have any real effect on voiding dysfunction in women?</article-title> <source>Current Urol Rep</source> <year>2011</year>; <volume>12</volume>: <fpage>345</fpage>–<lpage>350</lpage>.</citation></ref>
<ref id="bibr39-1754045313481536"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cardozo</surname><given-names>LD</given-names></name><name><surname>Rekers</surname><given-names>H</given-names></name><name><surname>Tapp</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Oestriol in the treatment of postmenopausal urgency: a multicentre study</article-title>. <source>Maturitas</source> <year>1993</year>; <volume>18</volume>: <fpage>47</fpage>–<lpage>53</lpage>.</citation></ref>
<ref id="bibr40-1754045313481536"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benness</surname><given-names>C</given-names></name><name><surname>Wise</surname><given-names>BG</given-names></name><name><surname>Cutner</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Does low dose vaginal oestradiol improve frequency and urgency in postmenopausal women</article-title>. <source>Int Urogynaecol J</source> <year>1992</year>; <volume>3</volume>: <fpage>281</fpage>–<lpage>281</lpage>.</citation></ref>
<ref id="bibr41-1754045313481536"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cardozo</surname><given-names>L</given-names></name><name><surname>Lose</surname><given-names>G</given-names></name><name><surname>McClish</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Estrogen treatment for symptoms of an overactive bladder, results of a meta-analysis</article-title>. <source>Int J Urogynaecol</source> <year>2001</year>; <volume>12</volume>: <fpage>V</fpage>–<lpage>V</lpage>.</citation></ref>
<ref id="bibr42-1754045313481536"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perrotta</surname><given-names>C</given-names></name><name><surname>Aznar</surname><given-names>M</given-names></name><name><surname>Mejia</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Oestrogens for preventing recurrent urinary tract infection in postmenopausal women</article-title>. <source>Cochrane Database Syst Rev</source> <year>2008</year>(<issue>2</issue>): <fpage>CD005131</fpage>–<lpage>CD005131</lpage>.</citation></ref>
<ref id="bibr43-1754045313481536"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brandberg</surname><given-names>A</given-names></name><name><surname>Mellstrom</surname><given-names>D</given-names></name><name><surname>Samsioe</surname><given-names>G</given-names></name></person-group>. <article-title>Low dose oral oestriol treatment in elderly women with urogenital infections</article-title>. <source>Acta Obstet Gynaecol Scand</source> <year>1987</year>; <volume>140</volume>: <fpage>33</fpage>–<lpage>38</lpage>.</citation></ref>
<ref id="bibr44-1754045313481536"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leckie</surname><given-names>KJ</given-names></name></person-group>. <article-title>What is the evidence for the role of oestrogen in the prevention of recurrent urinary tract infections in postmenopausal women? An evidence-based review</article-title>. <source>J Clin Gerontol Geriatr</source> <year>2010</year>; <volume>1</volume>: <fpage>31</fpage>–<lpage>35</lpage>.</citation></ref>
<ref id="bibr45-1754045313481536"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname><given-names>P</given-names></name><name><surname>Cardozo</surname><given-names>L</given-names></name><name><surname>Fall</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society</article-title>. <source>Neurourol Urodyn</source> <year>2002</year>; <volume>21</volume>: <fpage>167</fpage>–<lpage>168</lpage>.</citation></ref>
<ref id="bibr46-1754045313481536"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ingelman-Sundberg</surname><given-names>A</given-names></name><name><surname>Rosen</surname><given-names>J</given-names></name><name><surname>Gustafsson</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>Cytosol estrogen receptors in the urogenital tissues in stress-incontinent women</article-title>. <source>Acta Obstet Gynecol Scand</source> <year>1981</year>; <volume>60</volume>: <fpage>585</fpage>–<lpage>586</lpage>.</citation></ref>
<ref id="bibr47-1754045313481536"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>JH</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>ZJ</given-names></name><etal/></person-group>. <article-title>Oestrogen levels and oestrogen receptors in patients with stress urinary incontinence and pelvic organ prolapse</article-title>. <source>Int J Gynaecol Obstet</source> <year>2003</year>; <volume>80</volume>: <fpage>35</fpage>–<lpage>39</lpage>.</citation></ref>
<ref id="bibr48-1754045313481536"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vardy</surname><given-names>MD</given-names></name><name><surname>Scotti</surname><given-names>R</given-names></name><name><surname>Lindsay</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Short term urogenital effects of raloxifene, tamoxifen and estrogen</article-title>. <source>Int Urogynecol J</source> <year>2000</year>; <volume>11</volume>(<issue>S1</issue>): <fpage>O11</fpage>–<lpage>O11</lpage>.</citation></ref>
</ref-list>
</back>
</article>